# EDGAR Filing Document

**Accession Number:** 0001644162
**File Stem:** 0001178913-26-001960
**Filing Date:** 2026-3
**Character Count:** 6418
**Document Hash:** d5cb8c357a4546830f380c2ff55b81df
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-001960.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0001178913-26-001960

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Nicaise Claude
- **CENTRAL INDEX KEY:** 0001644162

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38807
- **FILM NUMBER:** 26821530

**MAIL ADDRESS:**
- **STREET 1:** 215 FIRST STREET, SUITE 415
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chemomab Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001534248
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 813676773
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** KIRYAT ATIDIM, BUILDING 7
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 972-77-331-0156

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** KIRYAT ATIDIM, BUILDING 7
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anchiano Therapeutics Ltd.
- **DATE OF NAME CHANGE:** 20180906

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioCancell Ltd.
- **DATE OF NAME CHANGE:** 20111104

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Nicaise Claude<br><sub>(Last) (First) (Middle)</sub><br>C/O CHEMOMAB THERAPEUTICS LTD.<br>10 HABARZEL STBUILDING C, 10TH FLOOR<br><sub>(Street)</sub><br>TEL AVIV, ISRAEL 6158101<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Chemomab Therapeutics Ltd. [ CMMB ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock option (right to buy American Depositary Shares) | <sup>(1)</sup> | 2031-04-19 | American Depositary Shares | 2971 | $109.04 | D |  |
| Stock option (right to buy American Depositary Shares) | <sup>(2)</sup> | 2032-03-07 | American Depositary Shares | 1705 | $14.12 | D |  |
| Stock option (right to buy American Depositary Shares) | <sup>(3)</sup> | 2033-03-21 | American Depositary Shares | 1714 | $6.48 | D |  |
| Stock option (right to buy American Depositary Shares) | <sup>(4)</sup> | 2034-03-18 | American Depositary Shares | 2520 | $2.96 | D |  |
| Stock option (right to buy American Depositary Shares) | <sup>(5)</sup> | 2035-03-16 | American Depositary Shares | 3821 | $6.16 | D |  |
| Stock option (right to buy American Depositary Shares) | 2027-03-16 | 2036-03-16 | American Depositary Shares | 5172 | $2.14 | D |  |

---

### Footnotes:

(1) The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.

(2) The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.

(3) The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.

(4) The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.

(5) The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.

**Remarks:**
This Form 3 has been filed after March 18, 2026 but prior to April 20, 2026 in reliance on the temporary relief made available to the directors and officers of certain foreign private issuers by the Staff of the Securities and Exchange Commission in its no-action letter dated March 13, 2026.

**Signature:** /s/ Claude Nicaise  
**Date:** 2026-03-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**